Advertisement
She also, in a tweet, said the company was working closely with the WHO for inclusion of Covaxin in its EUL and approval is not expected to be a long drawn process as cell line and majority of Bharat Biotech”s facilities have already been audited and approved by the global health watchdog for BBIL”s other vaccines in the past. The city-based vaccine maker recently said it concluded the final analysis of Covaxin efficacy from Phase 3 trials. The jab demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the B.1.617.2 Delta variant, it said. Advertisement
WHO assessing Covaxin data for EUL; Decision date "to be confirmed"
10:35 AM Jul 20, 2021 | PTI |
Advertisement
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.